DPH008

DPH008 is a preclinical-stage drug candidate being developed by Disruptive Pharma (also known as DISruptive Oncology) for the treatment of prostate cancer. The program utilizes the company's proprietary PharmaShell technology, which employs Atomic Layer Deposition (ALD) to apply a nanometer-thin, biocompatible coating to drug particles. This technology is designed to improve the solubility, stability, and pharmacokinetic profile of the active pharmaceutical ingredient, potentially allowing for controlled release or improved bioavailability. As of early 2025, the specific active ingredient and molecular mechanism of action for DPH008 have not been publicly disclosed by the developer.